The Journal of Rheumatology

91

J Rheumatol 2014;91;1-85
http://www.jrheum.org/content/91.citation

1. Sign up for TOCs and other alerts
http://www.jrheum.org/alerts

2. Information on Subscriptions
http://jrheum.com/faq

3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

*The Journal of Rheumatology* is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence

Introduction  Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence
F. Cantini, D. Goletti

Update on the Epidemiology of Tuberculosis in Italy
M. Conversano

The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics
G. Delogu, D. Goletti

Cellular and Humoral Immune Responses During Tuberculosis Infection:
Useful Knowledge in the Era of Biological Agents
A. Matucci, E. Maggi, A. Vultaggio

Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches
D. Goletti, A. Sanduzzi, G. Delogu

Diagnostic Accuracy of Chest Radiography for the Diagnosis of Tuberculosis (TB) and Its Role in the Detection of Latent TB Infection: a Systematic Review
R. Piccazzo, F. Paparo, G. Garlaschi

Diagnosis of Latent Tuberculosis and Prevention of Reactivation in Rheumatic Patients Receiving Biologic Therapy: International Recommendations
F. Iannone, F. Cantini, G. Lapadula

Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
F. Cantini, L. Niccoli, D. Goletti

Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
F. Cantini, L. Niccoli, D. Goletti

Tuberculosis Reactivation Risk in Dermatology
L. Pescitelli, F. Ricceri, F. Prignano

Current Treatment Options for Latent Tuberculosis Infection
M. Bocchino, A. Matarese, A. Sanduzzi

Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment
F. Cantini, F. Prignano, D. Goletti

Cost for Tuberculosis Care in Developed Countries: Which Data for an Economic Evaluation?
L. Trieste, G. Turchetti